
Repurposing approved drugs as ferroptosis modulators: a critical review of clinical trials in cancer and neurodegeneration
This review highlights the potential of ferroptosis modulation as a therapeutic strategy in cancer and neurodegenerative diseases. It examines clinical evidence from repurposed approved drugs with ferroptosis-modulating properties and explores the key barriers that have limited successful clinical translation.






